Fina Biosolutions LLC is a privately held research and development stage biotechnology company that discovers, develops, and collaborates to commercialize novel vaccine conjugates for prevention of life-threatening diseases. Fina has patented novel techniques to conjugate, purify, and manufacture conjugates using its proprietary chemistry to create complex conjugate vaccines. The technology is currently licensed by leading vaccine manufacturers in both Europe and Asia, including GlaxoSmithKline for marketed vaccines Synflorix™ Menitorix™, Nimenrix™, The Serum Institute of India Ltd., The Chengdu Institute of Biological Products and others. Fina Biosolutions also manufactures E. coli expressed CRM197 conjugate vaccine carrier protein.
Fina BioSolutions also develops polymer based diagnostic reagents, amino dextran, and antibody dextran conjugates.
Company Details
- Employees
- 10
- Founded
- -
- Address
- Rockville, Maryland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.finabio.com
- Keywords
- Conjugate vaccines, Bioconjugation, Protein Purification, Amino Dextran, Antibody Dextran Conjugates, CRM197.
- HQ
- Rockville, MARYLAND
Fina Biosolutions Llc Questions
Fina Biosolutions Llc's website is http://www.finabio.com
Fina Biosolutions Llc's LinkedIn profile is https://www.linkedin.com/company/fina-biosolutions-llc
Fina Biosolutions Llc has
10 employees.
View email and phone details for 10
employees at Fina Biosolutions Llc.
Fina Biosolutions Llc's industry is
Biotechnology Research
Fina Biosolutions Llc's top competitors are
Valanx Biotech,
Sequella, Inc.,
Ascentgene, Inc.,
Remedy Plan Therapeutics,
Sk Bioscience,
Jj Innovative Materials,
Omnium Global,
Cepi (Coalition For Epidemic Preparedness Innovations),
Leniobio,
City Therapeutics.
Fina Biosolutions Llc's categories are Biotechnology Research
Fina Biosolutions Llc's founding year is 2006
